A Phase 4 interventional study of Esomeprazole and Placebo in Gastroesophageal Reflux Disease, sponsored by AstraZeneca. Completed at 45 sites in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2015-03-02.
Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 67 studies testing esomeprazole in Gastroesophageal Reflux — 1 open to participants now, 1 under way, none of them phase 3. Esomeprazole · Gastroesophageal Reflux.
Among the 67 studies testing esomeprazole in Gastroesophageal Reflux, this one is the 23rd largest by enrollment of the 66 interventional ones that give a count, is one of 6 that started in 2008, is one of 28 in phase 4, and was the 41st registered.
1,215 studies on the registry are indexed under Gastroesophageal Reflux; 204 are open to participants now.
Browse Gastroesophageal Reflux studies →1 of the 67 studies testing esomeprazole in Gastroesophageal Reflux is open now, in 1 country. Recruiting first, the newest first:
Asian Institute of Gastroenterology, India · Sites in India
Ages 18–75
By country, each count listing its studies:
Esomeprazole: first FDA approval 2001 (NEXIUM), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 134 Gastroesophageal Reflux studies recruiting now, 58 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
67 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 8 · Phase 3 17 · Phase 4 28
First in 2001; this study’s year is marked. 6 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 276 is above the median of 68 across 800 interventional studies indexed under Gastroesophageal Reflux.
Median enrollment 125 across the 66 interventional studies. Of the 58 that completed or were terminated, 13 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
43 of 67 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
89 studies in Gastroesophageal Reflux by AstraZeneca: none open now, none under way, none of them phase 3. Of 89 finished, 15 (17%) have results posted.
Among the 89 studies in Gastroesophageal Reflux by AstraZeneca, this one is the 24th largest by enrollment of the 52 interventional ones that give a count, is one of 16 that started in 2008, is one of 21 in phase 4, and was the 43rd registered.
AstraZeneca’s Gastroesophageal Reflux studies by the year they started, since 1998.
1 of the studies testing esomeprazole in Gastroesophageal Reflux that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06953986Asian Institute of Gastroenterology, IndiaA Randomized, Three-Arm Study Comparing Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg for the Healing of LA Grade B or Higher Reflux Esophagitis at 8 Weeks | 2026-11-20 |
Add it to your calendar (.ics) → With an account.
Among the 67 studies testing esomeprazole in Gastroesophageal Reflux, from their registry updates:
Among AstraZeneca’s 89 in Gastroesophageal Reflux:
This tab as a report to print or save as PDF → With an account.
The purpose of this research study is to compare the safety and effectiveness (how well the medicine works) of esomeprazole (study drug) to placebo (a capsule that does not contain any medication) taken daily in relieving nighttime heartburn and problems sleeping in patients with gastroesophageal reflux disease (GERD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Nexium 20 mg administered once daily as 22.3 mg of esomeprazole magnesium hydrate
Drug: Esomeprazole
Drug: Placebo
Nexium 20 mg administered once daily as 22.3 mg of esomeprazole magnesium hydrate
Also known as: Nexium
once daily
Percentage of Patients With Relief of Nighttime Heartburn During the Last 7 Days of the Study.
Relief of nighttime heartburn on patient's last 7 days in the study. Relief was defined as a daily diary card response of "none" or 0, on at least 6 of 7 days, allowing for one "mild" or 1 response. Diary card scale (none, mild, moderate, severe).
Time frame: Days 21- 28 (for early dropouts the last 7 days staying in the study)
Change in Mean (Average) Pittsburgh Sleep Quality Index (PSQI) Scores From Baseline
To assess the impact of treatment as measured by: Change in global Pittsburgh Sleep Quality Index (PSQI) scores from baseline to week 4. Scale details -'Scoring ranged from 0, "no difficulty" to 3, "severe difficulty." Items were grouped into 7 component scores. The 7 components were then summed to yield a global PSQI score. Global scores \>5 were considered to meet the criteria of sleep disturbance.
Time frame: Baseline and 4 weeks
Achievement of Developer-defined Good Sleep
To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on sleep disturbances associated with Gastroesophageal reflux disease (GERD), as measured by achievement of (yes/no) developer-defined good sleep (global Pittsburgh Sleep Quality Index - PSQI score ≤5) at Week 4.
Time frame: 4 weeks
Number of Patients With Complete Resolution of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) After 1 Week of Treatment.
The assessment was based on patients registrations of the answers "Yes" or "No" to the question: "Did you have trouble sleeping last night due to your heartburn or other symptoms of Gastroesophageal Reflux Disease (GERD)?". Complete resolution of GERD-related sleep disturbances was defined as a daily diary response of "No" on 7 consecutive days.
Time frame: 1 week
Number of Patients With Complete Resolution of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) After 2 Weeks of Treatment.
The assessment was based on patients registrations of the answers "Yes" or "No" to the question: "Did you have trouble sleeping last night due to your heartburn or other symptoms of Gastroesophageal Reflux Disease (GERD)?". Complete resolution of GERD-related sleep disturbances was defined as a daily diary response of "No" on 14 consecutive days.
Time frame: 2 weeks
Number of Patients With Complete Resolution of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) After 4 Weeks of Treatment.
The assessment was based on patients registrations of the answers "Yes" or "No" to the question: "Did you have trouble sleeping last night due to your heartburn or other symptoms of GERD?". Complete resolution of Gastroesophageal Reflux Disease (GERD)-related sleep disturbances was defined as a daily diary response of "No" on 7 consecutive days during 4 weeks of treatment.
Time frame: 4 weeks
Number of Patients With Complete Resolution of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) on the Patient's Last 7 Days in the Study.
To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on sleep disturbances associated with Gastroesophageal Reflux Disease (GERD), as measured by: Complete resolution of sleep disturbances on the patient's last 7 days in the study.
Time frame: Days 21- 28 (for early dropouts the last 7 days staying in the study)
Number of Patients With Relief of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) After 1 Week of Treatment
The assessment was based on patients registrations of the answers "Yes" or "No" to the question: "Did you have trouble sleeping last night due to your heartburn or other symptoms of Gastroesophageal Reflux Disease (GERD)?". Relief of sleep disturbances associated with GERD was defined as a daily diary response of "Yes" on not more than 2 of 7 consecutive days.
Time frame: 1 week
Number of Patients With Relief of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) After 2 Weeks of Treatment
The assessment was based on patients registrations of the answers "Yes" or "No" to the question: "Did you have trouble sleeping last night due to your heartburn or other symptoms of Gastroesophageal Reflux Disease (GERD)?". Relief of sleep disturbances associated with GERD was defined as a daily diary response of "Yes" on not more than 2 of 7 consecutive days.
Time frame: 2 weeks
Number of Patients With Relief of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) After 4 Weeks of Treatment
The assessment was based on patients registrations of the answers "Yes" or "No" to the question: "Did you have trouble sleeping last night due to your heartburn or other symptoms of Gastroesophageal Reflux Disease (GERD)?". Relief of sleep disturbances associated with GERD was defined as a daily diary response of "Yes" on not more than 2 of 7 consecutive days.
Time frame: 4 weeks
Percentage of Patients With Relief of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) on the Patient's Last 7 Days in the Study.
The assessment was based on patients registrations of the answers "Yes" or "No" to the question: "Did you have trouble sleeping last night due to your heartburn or other symptoms of Gastroesophageal Reflux Disease (GERD)?". Relief of sleep disturbances associated with GERD was defined as a daily diary response of "Yes" on not more than 2 of 7 consecutive days.
Time frame: Days 21- 28 (for early dropouts the last 7 days staying in the study)
Percentage of Days Without Gastroesophageal Reflux Disease (GERD)-Related Sleep Disturbances During the 4 Week Period
To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on sleep disturbances associated with Gastroesophageal Reflux Disease (GERD)as measured by: Percent of days without sleep disturbances after 4 weeks of treatment. Each morning of the study, patients registered their answer "Yes" or "No" to the question, "Did you have trouble sleeping last night due to your heartburn or other symptoms of GERD?" in the diary card.'
Time frame: 4 weeks
Number of Days to First Relief of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) During the 4 Week Treatment Period
The assessment was based on patients registrations of the answers "Yes" or "No" to the question: "Did you have trouble sleeping last night due to your heartburn or other symptoms of Gastroesophageal Reflux Disease (GERD)?". Relief of sleep disturbances associated with GERD was defined as a daily diary response of "Yes" on not more than 2 of 7 consecutive days, and 'days to first relief' was defined as the first day of the 7 days that reached relief of sleep disturbance.
Time frame: 4 weeks
Number of Days to Resolution of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) During the 4 Week Treatment Period
The assessment was based on patients registrations of the answers "Yes" or "No" to the question: "Did you have trouble sleeping last night due to your heartburn or other symptoms of Gastroesophageal Reflux Disease (GERD)?". Relief of sleep disturbances associated with GERD was defined as a daily diary response of "Yes" on not more than 2 of 7 consecutive days.
Time frame: 4 weeks
Number of Days to First Complete Resolution of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) During the 4 Week Treatment Period
To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on sleep disturbances associated with Gastroesophageal Reflux Disease (GERD), as measured by: Days to complete resolution of sleep disturbance. Days to complete resolution of sleep disturbances associated with GERD was defined as the number of days until the first day of the first 7-consecutive-day period during which the patient's daily diary response was "No" (did not have trouble sleeping due to GERD symptoms).'
Time frame: 4 weeks
Percentage of Patients With Complete Resolution of Daytime Heartburn After 1 Week of Treatment
To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Complete resolution of daytime heartburn after 1 week of treatment. Results based on MITT population with available data for this outcome measure. Complete resolution of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "None" on 7 consecutive days.
Time frame: 1 week
Percentage of Patients With Complete Resolution of Daytime Heartburn After 2 Weeks of Treatment
To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Complete resolution of daytime heartburn after 2 weeks of treatment. Complete resolution of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "None" on 7 consecutive days.
Time frame: 2 weeks
Percentage of Patients With Complete Resolution of Daytime Heartburn After 4 Weeks of Treatment
To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Complete resolution of daytime heartburn after 4 weeks of treatment. Complete resolution of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "None" on 7 consecutive days.
Time frame: 4 weeks
Percentage of Patients With Complete Resolution of Daytime Heartburn on the Patient's Last 7 Days in the Study
To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Complete resolution of daytime heartburn on the patient's last 7 days in the study. Complete resolution of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "None" on 7 consecutive days.
Time frame: Days 21- 28 (for early dropouts the last 7 days staying in the study)
Percentage of Patients With Complete Resolution of Nighttime Heartburn After 1 Week of Treatment.
To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Complete resolution of nighttime heartburn after 1 week of treatment. Complete resolution of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "None" on 7 consecutive days.
Time frame: 1 week
Percentage of Patients With Complete Resolution of Nighttime Heartburn After 2 Weeks of Treatment
To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Complete resolution of nighttime heartburn after 2 weeks of treatment. Complete resolution of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "None" on 7 consecutive days.
Time frame: 2 weeks
Percentage of Patients With Complete Resolution of Nighttime Heartburn After 4 Weeks of Treatment
To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Complete resolution of nighttime heartburn after 4 weeks of treatment. Complete resolution of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "None" on 7 consecutive days.
Time frame: 4 weeks
Percentage of Patients With Complete Resolution of Nighttime Heartburn on the Patient's Last 7 Days in the Study.
To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Complete resolution of nighttime heartburn on the patient's last 7 days in the study. Complete resolution of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "None" on 7 consecutive days.
Time frame: Days 21- 28 (for early dropouts the last 7 days staying in the study)
Percentage of Patients With Complete Resolution of 24-hour Heartburn After 1 Week of Treatment
To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Complete resolution of 24-hour heartburn after 1 week of treatment. Complete resolution of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "None" on 7 consecutive days.
Time frame: 1 week
Percentage of Patients With Complete Resolution of 24-hour Heartburn After 2 Weeks of Treatment
To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Complete resolution of 24-hour heartburn after 2 weeks of treatment. Complete resolution of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "None" on 7 consecutive days.
Time frame: 2 weeks
Percentage of Patients With Complete Resolution of 24-hour Heartburn After 4 Weeks of Treatment
To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Complete resolution of 24-hour heartburn after 4 weeks of treatment. Complete resolution of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "None" on 7 consecutive days.
Time frame: 4 weeks
Percentage of Patients With Complete Resolution of 24-hour Heartburn on the Patient's Last 7 Days in the Study
To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Complete resolution of 24-hour heartburn on the patient's last 7 days in the study. Complete resolution of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "None" on 7 consecutive days.
Time frame: Days 21- 28 (for early dropouts the last 7 days staying in the study)
Percentage of Patients With Relief of Daytime Heartburn After 1 Week of Treatment
To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Relief of daytime heartburn after 2 weeks of treatment. Results based on MITT population with available data for this outcome measure. Relief of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "none" on at least 6 of 7 days, allowing for 1 "mild" response.'
Time frame: 1 week
Percentage of Patients With Relief of Daytime Heartburn After 2 Weeks of Treatment
To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Relief of daytime heartburn after 2 weeks of treatment. Relief of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "none" on at least 6 of 7 days, allowing for 1 "mild" response.'
Time frame: 2 weeks
Percentage of Patients With Relief of Daytime Heartburn After 4 Weeks of Treatment
To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Relief of daytime heartburn after 4 weeks of treatment. Relief of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "none" on at least 6 of 7 days, allowing for 1 "mild" response.'
Time frame: 4 weeks
Percentage of Patients With Relief of Daytime Heartburn on the Patient's Last 7 Days in the Study
To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Relief of daytime heartburn on the patient's last 7 days in the study. Relief of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "none" on at least 6 of 7 days, allowing for 1 "mild" response.'
Time frame: Days 21- 28 (for early dropouts the last 7 days staying in the study)
Percentage of Patients With Relief of Nighttime Heartburn After 1 Week of Treatment.
To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Relief of nighttime heartburn after 1 week of treatment. Relief of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "none" on at least 6 of 7 days, allowing for 1 "mild" response.
Time frame: 1 week
Percentage of Patients With Relief of Nighttime Heartburn After 2 Weeks of Treatment
To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Relief of nighttime heartburn after 2 weeks of treatment. Relief of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "none" on at least 6 of 7 days, allowing for 1 "mild" response.
Time frame: 2 weeks
Percentage of Patients With Relief of Nighttime Heartburn After 4 Weeks of Treatment
To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Relief of nighttime heartburn after 4 weeks of treatment. Relief of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "none" on at least 6 of 7 days, allowing for 1 "mild" response.
Time frame: 4 weeks
Percentage of Patients With Relief of Nighttime Heartburn on the Patient's Last 7 Days in the Study
To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Relief of nighttime heartburn on the patient's last 7 days in the study. Relief of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "none" on at least 6 of 7 days, allowing for 1 "mild" response.
Time frame: Days 21- 28 (for early dropouts the last 7 days staying in the study)
Percentage of Patients With Relief of 24-hour Heartburn After 1 Week of Treatment
To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Relief of 24-hour heartburn after 1 week of treatment. Relief of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "none" on at least 6 of 7 days, allowing for 1 "mild" response.
Time frame: 1 week
Percentage of Patients With Relief of 24-hour Heartburn After 2 Weeks of Treatment
To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Relief of 24-hour heartburn after 2 weeks of treatment. Relief of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "none" on at least 6 of 7 days, allowing for 1 "mild" response.
Time frame: 2 weeks
Percentage of Patients With Relief of 24-hour Heartburn After 4 Weeks of Treatment
To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Relief of 24-hour heartburn after 4 weeks of treatment. Relief of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "none" on at least 6 of 7 days, allowing for 1 "mild" response.
Time frame: 4 weeks
Percentage of Patients With Relief of 24-hour Heartburn on the Patient's Last 7 Days in the Study
To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Relief of 24-hour heartburn on the patient's last 7 days in the study. Relief of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "none" on at least 6 of 7 days, allowing for 1 "mild" response.
Time frame: Days 21- 28 (for early dropouts the last 7 days staying in the study)
Percentage of Patients With Nighttime Heartburn Symptom Improvement From Baseline During the Last 7 Days in the Study
Number and percentage of patients with nighttime heartburn symptom improvement based on weekly symptom scores at Baseline compared to the last week of study drug treatment. Symptom improvement was defined as any decrease in weekly symptom score from Baseline until the last 7 days in the study.
Time frame: Days 21- 28 (for early dropouts the last 7 days staying in the study)
Percentage of Participants With Daytime Heartburn Symptom Improvement From Baseline During the Last 7 Days in the Study
Number of patients with daytime heartburn symptom improvement based on weekly symptom scores at Baseline compared to the last week of study drug treatment. Symptom improvement was defined as any decrease in weekly symptom score from Baseline until the last 7 days in the study.
Time frame: Days 21-28 (for early dropouts the last 7 days staying in the study)
Percentage of Patients With 24-hour Heartburn Symptom Improvement From Baseline During the Last 7 Days in the Study.
Number of patients with 24-hour heartburn symptom improvement based on weekly symptom scores at Baseline compared to the last week of study drug treatment. Symptom improvement was defined as any decrease in weekly symptom score from Baseline until the last 7 days in the study.
Time frame: Days 21- 28 (for early dropouts the last 7 days staying in the study)
Equivalent Number of Hours Lost Because of Sleep Disturbances Due to Gastroesophageal Reflux Disease (GERD) Symptoms (Average)
Time frame: 4 weeks
Change From Baseline in Percent of Work Impairment Because of Sleep Disturbances Due to Gastroesophageal Reflux Disease (GERD) Symptoms (Average)
Degree of sleep disturbance affecting work productivity. 100% is considered to be the worst outcome where there is no ability to work. 0% is considered to be the best outcome, no impairment.
Time frame: Baseline and 4 weeks
Change From Baseline in Percent Overall Work Impairment Due to Sleep Disturbance (Average)
Equivalent number of work hours missed was derived from questions 2, 4 and 5 of the Work Productivity and Activity Impairment Questionnaire: Sleep Disturbance-GERD (Gastroesophageal Reflux Disease) and summed up with the percent work impairment during the remaining hours that were actually worked.
Time frame: Baseline and 4 weeks
Change From Baseline in Percent Activity Impairment Due to Sleep Disturbances (Average)
To assess the impact of treatment as measured by: Change in global Pittsburgh Sleep Quality Index (PSQI) scores from baseline to week 4. Scale details -'Scoring ranged from 0, "no difficulty" to 3, "severe difficulty." Items were grouped into 7 component scores. The 7 components were then summed to yield a global PSQI score. Global scores \>5 were considered to meet the criteria of sleep disturbance.
Time frame: Baseline and 4 weeks
Monetary Value of Work Hours Saved
The monetary value of the work hours saved was derived from questions 2,4, and 5 of the WPAI and a standard hourly compensation rate reported by the US Bureau of Labor Statistics (US$28.48 as of June 2008).
Time frame: Week 4
The baseline figures shown will be for the modified intention to treat population. One patient in each treatment group did not receive study drug; therefore, the safety population has one less patient in each treatment than does the randomized study population.
| Milestone | Nexium 20 mg | Placebo |
|---|---|---|
| Started | 143 | 133 |
| Met criteria for mitt population | 137 | 125 |
| Completed | 138 | 124 |
| Not completed | 5 | 9 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 6 |
| Withdrew: Lack of efficacy | 0 | 2 |
| Withdrew: Withdrawal by subject | 3 | 0 |
| Withdrew: Incorrect enrollment and other | 0 | 1 |
| Withdrew: New medication after randomization | 1 | 0 |
Relief of nighttime heartburn on patient's last 7 days in the study. Relief was defined as a daily diary card response of "none" or 0, on at least 6 of 7 days, allowing for one "mild" or 1 response. Diary card scale (none, mild, moderate, severe).
| Percentage of participants | Nexium 20 mg | Placebo |
|---|---|---|
| Percentage of Patients With Relief of Nighttime Heartburn During the Last 7 Days of the Study. | 34.3 | 10.4 |
To assess the impact of treatment as measured by: Change in global Pittsburgh Sleep Quality Index (PSQI) scores from baseline to week 4. Scale details -'Scoring ranged from 0, "no difficulty" to 3, "severe difficulty." Items were grouped into 7 component scores. The 7 components were then summed to yield a global PSQI score. Global scores \>5 were considered to meet the criteria of sleep disturbance.
| Scores on a scale | Nexium 20 mg | Placebo |
|---|---|---|
| Change in Mean (Average) Pittsburgh Sleep Quality Index (PSQI) Scores From Baseline | -2.93 ± 0.34 | -1.80 ± 0.34 |
To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on sleep disturbances associated with Gastroesophageal reflux disease (GERD), as measured by achievement of (yes/no) developer-defined good sleep (global Pittsburgh Sleep Quality Index - PSQI score ≤5) at Week 4.
| Participants | Nexium 20 mg | Placebo |
|---|---|---|
| Achievement of Developer-defined Good Sleep | 19 | 24 |
The assessment was based on patients registrations of the answers "Yes" or "No" to the question: "Did you have trouble sleeping last night due to your heartburn or other symptoms of Gastroesophageal Reflux Disease (GERD)?". Complete resolution of GERD-related sleep disturbances was defined as a daily diary response of "No" on 7 consecutive days.
| Participants | Nexium 20 mg | Placebo |
|---|---|---|
| Number of Patients With Complete Resolution of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) After 1 Week of Treatment. | 44 | 23 |
The assessment was based on patients registrations of the answers "Yes" or "No" to the question: "Did you have trouble sleeping last night due to your heartburn or other symptoms of Gastroesophageal Reflux Disease (GERD)?". Complete resolution of GERD-related sleep disturbances was defined as a daily diary response of "No" on 14 consecutive days.
| Participants | Nexium 20 mg | Placebo |
|---|---|---|
| Number of Patients With Complete Resolution of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) After 2 Weeks of Treatment. | 54 | 20 |
The assessment was based on patients registrations of the answers "Yes" or "No" to the question: "Did you have trouble sleeping last night due to your heartburn or other symptoms of GERD?". Complete resolution of Gastroesophageal Reflux Disease (GERD)-related sleep disturbances was defined as a daily diary response of "No" on 7 consecutive days during 4 weeks of treatment.
| Participants | Nexium 20 mg | Placebo |
|---|---|---|
| Number of Patients With Complete Resolution of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) After 4 Weeks of Treatment. | 29 | 14 |
To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on sleep disturbances associated with Gastroesophageal Reflux Disease (GERD), as measured by: Complete resolution of sleep disturbances on the patient's last 7 days in the study.
| Participants | Nexium 20 mg | Placebo |
|---|---|---|
| Number of Patients With Complete Resolution of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) on the Patient's Last 7 Days in the Study. | 66 | 27 |
The assessment was based on patients registrations of the answers "Yes" or "No" to the question: "Did you have trouble sleeping last night due to your heartburn or other symptoms of Gastroesophageal Reflux Disease (GERD)?". Relief of sleep disturbances associated with GERD was defined as a daily diary response of "Yes" on not more than 2 of 7 consecutive days.
| Participants | Nexium 20 mg | Placebo |
|---|---|---|
| Number of Patients With Relief of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) After 1 Week of Treatment | 79 | 53 |
The assessment was based on patients registrations of the answers "Yes" or "No" to the question: "Did you have trouble sleeping last night due to your heartburn or other symptoms of Gastroesophageal Reflux Disease (GERD)?". Relief of sleep disturbances associated with GERD was defined as a daily diary response of "Yes" on not more than 2 of 7 consecutive days.
| Participants | Nexium 20 mg | Placebo |
|---|---|---|
| Number of Patients With Relief of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) After 2 Weeks of Treatment | 90 | 54 |
The assessment was based on patients registrations of the answers "Yes" or "No" to the question: "Did you have trouble sleeping last night due to your heartburn or other symptoms of Gastroesophageal Reflux Disease (GERD)?". Relief of sleep disturbances associated with GERD was defined as a daily diary response of "Yes" on not more than 2 of 7 consecutive days.
| Participants | Nexium 20 mg | Placebo |
|---|---|---|
| Number of Patients With Relief of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) After 4 Weeks of Treatment | 74 | 45 |
The assessment was based on patients registrations of the answers "Yes" or "No" to the question: "Did you have trouble sleeping last night due to your heartburn or other symptoms of Gastroesophageal Reflux Disease (GERD)?". Relief of sleep disturbances associated with GERD was defined as a daily diary response of "Yes" on not more than 2 of 7 consecutive days.
| Percentage of Participants | Nexium 20 mg | Placebo |
|---|---|---|
| Percentage of Patients With Relief of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) on the Patient's Last 7 Days in the Study. | 71.5 | 55.2 |
To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on sleep disturbances associated with Gastroesophageal Reflux Disease (GERD)as measured by: Percent of days without sleep disturbances after 4 weeks of treatment. Each morning of the study, patients registered their answer "Yes" or "No" to the question, "Did you have trouble sleeping last night due to your heartburn or other symptoms of GERD?" in the diary card.'
| Percentage of days | Nexium 20 mg | Placebo |
|---|---|---|
| Percentage of Days Without Gastroesophageal Reflux Disease (GERD)-Related Sleep Disturbances During the 4 Week Period | 73.0 ± 29.7 | 59.3 ± 29.9 |
The assessment was based on patients registrations of the answers "Yes" or "No" to the question: "Did you have trouble sleeping last night due to your heartburn or other symptoms of Gastroesophageal Reflux Disease (GERD)?". Relief of sleep disturbances associated with GERD was defined as a daily diary response of "Yes" on not more than 2 of 7 consecutive days, and 'days to first relief' was defined as the first day of the 7 days that reached relief of sleep disturbance.
| Days | Nexium 20 mg | Placebo |
|---|---|---|
| Number of Days to First Relief of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) During the 4 Week Treatment Period | 1 (1 to 21) | 3 (1 to 21) |
The assessment was based on patients registrations of the answers "Yes" or "No" to the question: "Did you have trouble sleeping last night due to your heartburn or other symptoms of Gastroesophageal Reflux Disease (GERD)?". Relief of sleep disturbances associated with GERD was defined as a daily diary response of "Yes" on not more than 2 of 7 consecutive days.
| Days | Nexium 20 mg | Placebo |
|---|---|---|
| Number of Days to Resolution of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) During the 4 Week Treatment Period | 1 (1 to 14) | 2 (1 to 21) |
To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on sleep disturbances associated with Gastroesophageal Reflux Disease (GERD), as measured by: Days to complete resolution of sleep disturbance. Days to complete resolution of sleep disturbances associated with GERD was defined as the number of days until the first day of the first 7-consecutive-day period during which the patient's daily diary response was "No" (did not have trouble sleeping due to GERD symptoms).'
| Days | Nexium 20 mg | Placebo |
|---|---|---|
| Number of Days to First Complete Resolution of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) During the 4 Week Treatment Period | 9 (1 to 21) | 21 (1 to 21) |
To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Complete resolution of daytime heartburn after 1 week of treatment. Results based on MITT population with available data for this outcome measure. Complete resolution of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "None" on 7 consecutive days.
| Percentage of participants | Nexium 20 mg | Placebo |
|---|---|---|
| Percentage of Patients With Complete Resolution of Daytime Heartburn After 1 Week of Treatment | 22 | 4 |
To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Complete resolution of daytime heartburn after 2 weeks of treatment. Complete resolution of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "None" on 7 consecutive days.
| Percentage of participants | Nexium 20 mg | Placebo |
|---|---|---|
| Percentage of Patients With Complete Resolution of Daytime Heartburn After 2 Weeks of Treatment | 37 | 11 |
To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Complete resolution of daytime heartburn after 4 weeks of treatment. Complete resolution of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "None" on 7 consecutive days.
| Percentage of participants | Nexium 20 mg | Placebo |
|---|---|---|
| Percentage of Patients With Complete Resolution of Daytime Heartburn After 4 Weeks of Treatment | 35 | 7 |
To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Complete resolution of daytime heartburn on the patient's last 7 days in the study. Complete resolution of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "None" on 7 consecutive days.
| Percentage of participants | Nexium 20 mg | Placebo |
|---|---|---|
| Percentage of Patients With Complete Resolution of Daytime Heartburn on the Patient's Last 7 Days in the Study | 45 | 9 |
To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Complete resolution of nighttime heartburn after 1 week of treatment. Complete resolution of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "None" on 7 consecutive days.
| Percentage of participants | Nexium 20 mg | Placebo |
|---|---|---|
| Percentage of Patients With Complete Resolution of Nighttime Heartburn After 1 Week of Treatment. | 23 | 4 |
To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Complete resolution of nighttime heartburn after 2 weeks of treatment. Complete resolution of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "None" on 7 consecutive days.
| Percentage of participants | Nexium 20 mg | Placebo |
|---|---|---|
| Percentage of Patients With Complete Resolution of Nighttime Heartburn After 2 Weeks of Treatment | 36 | 6 |
To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Complete resolution of nighttime heartburn after 4 weeks of treatment. Complete resolution of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "None" on 7 consecutive days.
| Percentage of participants | Nexium 20 mg | Placebo |
|---|---|---|
| Percentage of Patients With Complete Resolution of Nighttime Heartburn After 4 Weeks of Treatment | 25 | 6 |
To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Complete resolution of nighttime heartburn on the patient's last 7 days in the study. Complete resolution of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "None" on 7 consecutive days.
| Percentage of participants | Nexium 20 mg | Placebo |
|---|---|---|
| Percentage of Patients With Complete Resolution of Nighttime Heartburn on the Patient's Last 7 Days in the Study. | 42 | 8 |
To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Complete resolution of 24-hour heartburn after 1 week of treatment. Complete resolution of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "None" on 7 consecutive days.
| Percentage of participants | Nexium 20 mg | Placebo |
|---|---|---|
| Percentage of Patients With Complete Resolution of 24-hour Heartburn After 1 Week of Treatment | 16 | 3 |
To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Complete resolution of 24-hour heartburn after 2 weeks of treatment. Complete resolution of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "None" on 7 consecutive days.
| Percentage of participants | Nexium 20 mg | Placebo |
|---|---|---|
| Percentage of Patients With Complete Resolution of 24-hour Heartburn After 2 Weeks of Treatment | 30 | 4 |
To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Complete resolution of 24-hour heartburn after 4 weeks of treatment. Complete resolution of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "None" on 7 consecutive days.
| Percentage of participants | Nexium 20 mg | Placebo |
|---|---|---|
| Percentage of Patients With Complete Resolution of 24-hour Heartburn After 4 Weeks of Treatment | 30 | 4 |
To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Complete resolution of 24-hour heartburn on the patient's last 7 days in the study. Complete resolution of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "None" on 7 consecutive days.
| Percentage of participants | Nexium 20 mg | Placebo |
|---|---|---|
| Percentage of Patients With Complete Resolution of 24-hour Heartburn on the Patient's Last 7 Days in the Study | 37 | 5 |
To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Relief of daytime heartburn after 2 weeks of treatment. Results based on MITT population with available data for this outcome measure. Relief of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "none" on at least 6 of 7 days, allowing for 1 "mild" response.'
| Percentage of participants | Nexium 20 mg | Placebo |
|---|---|---|
| Percentage of Patients With Relief of Daytime Heartburn After 1 Week of Treatment | 34 | 13 |
To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Relief of daytime heartburn after 2 weeks of treatment. Relief of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "none" on at least 6 of 7 days, allowing for 1 "mild" response.'
| Percentage of participants | Nexium 20 mg | Placebo |
|---|---|---|
| Percentage of Patients With Relief of Daytime Heartburn After 2 Weeks of Treatment | 48 | 14 |
To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Relief of daytime heartburn after 4 weeks of treatment. Relief of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "none" on at least 6 of 7 days, allowing for 1 "mild" response.'
| Percentage of participants | Nexium 20 mg | Placebo |
|---|---|---|
| Percentage of Patients With Relief of Daytime Heartburn After 4 Weeks of Treatment | 40 | 9 |
To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Relief of daytime heartburn on the patient's last 7 days in the study. Relief of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "none" on at least 6 of 7 days, allowing for 1 "mild" response.'
| Percentage of participants | Nexium 20 mg | Placebo |
|---|---|---|
| Percentage of Patients With Relief of Daytime Heartburn on the Patient's Last 7 Days in the Study | 55 | 14 |
To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Relief of nighttime heartburn after 1 week of treatment. Relief of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "none" on at least 6 of 7 days, allowing for 1 "mild" response.
| Percentage of participants | Nexium 20 mg | Placebo |
|---|---|---|
| Percentage of Patients With Relief of Nighttime Heartburn After 1 Week of Treatment. | 28 | 9 |
To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Relief of nighttime heartburn after 2 weeks of treatment. Relief of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "none" on at least 6 of 7 days, allowing for 1 "mild" response.
| Percentage of participants | Nexium 20 mg | Placebo |
|---|---|---|
| Percentage of Patients With Relief of Nighttime Heartburn After 2 Weeks of Treatment | 40 | 7 |
To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Relief of nighttime heartburn after 4 weeks of treatment. Relief of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "none" on at least 6 of 7 days, allowing for 1 "mild" response.
| Percentage of participants | Nexium 20 mg | Placebo |
|---|---|---|
| Percentage of Patients With Relief of Nighttime Heartburn After 4 Weeks of Treatment | 26 | 6 |
To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Relief of nighttime heartburn on the patient's last 7 days in the study. Relief of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "none" on at least 6 of 7 days, allowing for 1 "mild" response.
| Percentage of participants | Nexium 20 mg | Placebo |
|---|---|---|
| Percentage of Patients With Relief of Nighttime Heartburn on the Patient's Last 7 Days in the Study | 47 | 13 |
To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Relief of 24-hour heartburn after 1 week of treatment. Relief of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "none" on at least 6 of 7 days, allowing for 1 "mild" response.
| Percentage of participants | Nexium 20 mg | Placebo |
|---|---|---|
| Percentage of Patients With Relief of 24-hour Heartburn After 1 Week of Treatment | 27 | 5 |
To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Relief of 24-hour heartburn after 2 weeks of treatment. Relief of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "none" on at least 6 of 7 days, allowing for 1 "mild" response.
| Percentage of participants | Nexium 20 mg | Placebo |
|---|---|---|
| Percentage of Patients With Relief of 24-hour Heartburn After 2 Weeks of Treatment | 36 | 5 |
To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Relief of 24-hour heartburn after 4 weeks of treatment. Relief of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "none" on at least 6 of 7 days, allowing for 1 "mild" response.
| Percentage of participants | Nexium 20 mg | Placebo |
|---|---|---|
| Percentage of Patients With Relief of 24-hour Heartburn After 4 Weeks of Treatment | 33 | 5 |
To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Relief of 24-hour heartburn on the patient's last 7 days in the study. Relief of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "none" on at least 6 of 7 days, allowing for 1 "mild" response.
| Percentage of participants | Nexium 20 mg | Placebo |
|---|---|---|
| Percentage of Patients With Relief of 24-hour Heartburn on the Patient's Last 7 Days in the Study | 45 | 9 |
Number and percentage of patients with nighttime heartburn symptom improvement based on weekly symptom scores at Baseline compared to the last week of study drug treatment. Symptom improvement was defined as any decrease in weekly symptom score from Baseline until the last 7 days in the study.
| Percentage of participants | Nexium 20 mg | Placebo |
|---|---|---|
| Percentage of Patients With Nighttime Heartburn Symptom Improvement From Baseline During the Last 7 Days in the Study | 89.8 | 83.2 |
Number of patients with daytime heartburn symptom improvement based on weekly symptom scores at Baseline compared to the last week of study drug treatment. Symptom improvement was defined as any decrease in weekly symptom score from Baseline until the last 7 days in the study.
| Percentage of participants | Nexium 20 mg | Placebo |
|---|---|---|
| Percentage of Participants With Daytime Heartburn Symptom Improvement From Baseline During the Last 7 Days in the Study | 86.1 | 76 |
Number of patients with 24-hour heartburn symptom improvement based on weekly symptom scores at Baseline compared to the last week of study drug treatment. Symptom improvement was defined as any decrease in weekly symptom score from Baseline until the last 7 days in the study.
| Percentage of participants | Nexium 20 mg | Placebo |
|---|---|---|
| Percentage of Patients With 24-hour Heartburn Symptom Improvement From Baseline During the Last 7 Days in the Study. | 89.8 | 80 |
| Work hours | Nexium 20 mg | Placebo |
|---|---|---|
| Equivalent Number of Hours Lost Because of Sleep Disturbances Due to Gastroesophageal Reflux Disease (GERD) Symptoms (Average) | 8.9 ± 11.1 | 5.2 ± 11.7 |
Degree of sleep disturbance affecting work productivity. 100% is considered to be the worst outcome where there is no ability to work. 0% is considered to be the best outcome, no impairment.
| Percentage | Nexium 20 mg | Placebo |
|---|---|---|
| Change From Baseline in Percent of Work Impairment Because of Sleep Disturbances Due to Gastroesophageal Reflux Disease (GERD) Symptoms (Average) | -25.3 ± 28.7 | -14 ± 27.4 |
Equivalent number of work hours missed was derived from questions 2, 4 and 5 of the Work Productivity and Activity Impairment Questionnaire: Sleep Disturbance-GERD (Gastroesophageal Reflux Disease) and summed up with the percent work impairment during the remaining hours that were actually worked.
| Percentage | Nexium 20 mg | Placebo |
|---|---|---|
| Change From Baseline in Percent Overall Work Impairment Due to Sleep Disturbance (Average) | -24.8 ± 29.5 | -14.9 ± 25.9 |
To assess the impact of treatment as measured by: Change in global Pittsburgh Sleep Quality Index (PSQI) scores from baseline to week 4. Scale details -'Scoring ranged from 0, "no difficulty" to 3, "severe difficulty." Items were grouped into 7 component scores. The 7 components were then summed to yield a global PSQI score. Global scores \>5 were considered to meet the criteria of sleep disturbance.
| Percentage | Nexium 20 mg | Placebo |
|---|---|---|
| Change From Baseline in Percent Activity Impairment Due to Sleep Disturbances (Average) | -25.1 ± 27.4 | -17.1 ± 28 |
The monetary value of the work hours saved was derived from questions 2,4, and 5 of the WPAI and a standard hourly compensation rate reported by the US Bureau of Labor Statistics (US$28.48 as of June 2008).
| Monetary value (US dollars) | Nexium 20 mg | Placebo |
|---|---|---|
| Monetary Value of Work Hours Saved | 280.21 ± 34.88 | 156.61 ± 33.05 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nexium 20 mg | — | 0/143 (0%) | 0/143 (0%) |
| Placebo | — | 1/133 (0.8%) | 0/133 (0%) |
| Event | Nexium 20 mg | Placebo |
|---|---|---|
| PneumoniaInfections and infestations | 0/143 | 1/133 |
| Age, Continuous(Years) | Nexium 20 mg | Placebo | Total |
|---|---|---|---|
| Mean | 47.0 ± 11.7 | 46.8 ± 12.9 | 46.9 ± 12.3 |
| Sex: Female, Male(Participants) | Nexium 20 mg | Placebo | Total |
|---|---|---|---|
| Female | 89 | 85 | 174 |
| Male | 48 | 40 | 88 |
The record gives a start of Apr 2008, a primary completion of Jul 2008 and a completion of Jul 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2015, 6 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Esomeprazole